

ASX ANNOUNCEMENT

21 September 2018

Appendix 3Y – Change of Director’s Interest Notice

DigitalX Ltd (**DigitalX** or the **Company**) advises that on 4 December 2017, the Company’s Chairman, Mr Peter Rubinstein, sold 210,000 fully paid ordinary shares in the Company. Due to an oversight the sale was thought to have been included in the 1 December 2017 Notice, and as a result the Company Secretary was not informed of the sale of shares and did not lodge the required notification pursuant to ASX Listing Rule 3.19A.2.

The attached Appendix 3Y reflects the change to Mr Rubinstein’s interest on 6 December 2017.

The Company and its Directors are aware of their obligations under ASX Listing Rule 3.19A. The Company has a formal policy in place which requires all Directors to notify the Company Secretary of all transactions involving buying or selling the Company’s shares immediately after the transactions have occurred.

Notwithstanding this inadvertent oversight, the Company and its Directors consider the current arrangements are adequate to ensure further compliance with ASX Listing Rule 3.19B.

-ENDS-

For further information, please contact

DigitalX Limited
Leigh Travers
Managing Director
leigh@digitalx.com
T: +61 439 376 847

About DigitalX

DigitalX is positioned as the leading publicly listed ICO and STO corporate advisory firm globally. DigitalX is based out of Perth and New York and provides ICO/STO advisory services, Blockchain consulting services, cryptoasset funds management through DigitalX Investments and Blockchain education through Coincast Media.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	DigitalX Limited
ABN	59 009 575 035

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	18 September 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. Peter Irwin Rubinstein is the sole director and shareholder of Irwin Biotech Nominees Pty Ltd and a beneficiary of BIOA Trust.
Date of change	4 December 2017

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change¹</p> <p>1. Includes securities notified in Appendix 3Y dated 18 September 2018</p>	<p>Direct</p> <p>617,284 Subscription Options exercisable at \$0.0324 each on or before 1 September 2020</p> <p>Indirect</p> <p>13,476,296 Fully Paid Ordinary Shares¹</p> <p>3,000,000 Fully Paid Ordinary Shares²</p> <p>7,000,000 Fully Paid Ordinary Shares³</p> <p>3,400,000 Incentive Options exercisable at \$0.0324 each on or before 18 September 2020¹</p> <p>1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust.</p> <p>2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund.</p> <p>3. Held by ValueAdmin.Com Pty Ltd.</p>
<p>Class</p>	<p>Fully Paid Ordinary Shares</p>
<p>Number acquired</p>	<p>Nil</p>
<p>Number disposed</p>	<p>210,000 Fully Paid Ordinary Shares</p>
<p>Value/Consideration</p> <p>Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$0.24 per Share</p>
<p>No. of securities held after change</p>	<p>Direct</p> <p>617,284 Subscription Options exercisable at \$0.0324 each on or before 1 September 2020</p> <p>Indirect</p> <p>13,266,296 Fully Paid Ordinary Shares¹</p> <p>3,000,000 Fully Paid Ordinary Shares²</p> <p>7,000,000 Fully Paid Ordinary Shares³</p> <p>3,400,000 Incentive Options exercisable at \$0.0324 each on or before 18 September 2020¹</p> <p>1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust.</p> <p>2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund.</p> <p>3. Held by ValueAdmin.Com Pty Ltd.</p>

+ See chapter 19 for defined terms.

For personal use only

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On Market Sale
--	----------------

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only